Acurx Pharmaceuticals Inc (NAS:ACXP)

Q4 2024 Acurx Pharmaceuticals Inc Earnings Call Transcript

Mar 18, 2025 / 12:00 PM GMT

Release Date Price: $8.12 (-14.23%)

Transcript 8-K10-K

Key Points

Positve

Acurx Pharmaceuticals Inc (ACXP) is advancing its lead antibiotic candidate, Ibezapolstat, into international phase 3 clinical trials for C. difficile infection.
The company reported a high clinical cure rate of 96% in phase 2 trials, with 100% of Ibezapolstat-treated patients remaining cured one month after treatment.
Acurx Pharmaceuticals Inc (ACXP) received positive regulatory guidance from both the FDA and the European Medicines Agency, aligning their phase 3 clinical trial program.
The company closed a $2.5 million registered direct offering and a $1.1 million private placement, strengthening its financial position.
A new patent was granted by the Japanese patent office for DNA gyrase inhibitors, extending intellectual property protection until December 2039.

Negative

Acurx Pharmaceuticals Inc (ACXP) ended the year with a reduced cash position of $3.7 million, down from $7.5 million the previous year.
The company reported a net loss of $2.8 million for the fourth quarter of 2024, indicating ongoing financial challenges.
Research and development expenses decreased, primarily due to reduced consulting costs, but manufacturing costs increased.
General and administrative expenses increased slightly for the year, driven by higher professional and legal fees.
The company faces challenges in securing partnerships and funding, with market turmoil impacting potential collaborations.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ACXP.OQ - Acurx Pharmaceuticals Inc
Q4 2024 Acurx Pharmaceuticals Inc Earnings Call
Mar 18, 2025 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Greetings and welcome to the Accurate Pharmaceutical. 4th quarter and full year 2024 financial results and business update. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation.

If anyone should require operator assistance during the conference, please press star 0 on your telephone keypad. As a reminder, this conference is being recorded. I'll now turn the conference over to your host, Mr. Rob Shala, Chief Financial Officer for Accur Pharmaceuticals. Please go ahead, sir.

--------------------------------------------------------------------------------
Unidentified_2 [2]
---------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.